Breathing new life into immunotherapy

Review of melanoma, lung and kidney cancer

Charles G. Drake, Evan Lipson, Julie Brahmer

Research output: Contribution to journalArticle

Abstract

Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints - whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.

Original languageEnglish (US)
Pages (from-to)24-37
Number of pages14
JournalNature Reviews Clinical Oncology
Volume11
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Kidney Neoplasms
Immunotherapy
Melanoma
Lung Neoplasms
Respiration
Neoplasms
Vaccines
Cancer Vaccines
Immune System
Monoclonal Antibodies

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Breathing new life into immunotherapy : Review of melanoma, lung and kidney cancer. / Drake, Charles G.; Lipson, Evan; Brahmer, Julie.

In: Nature Reviews Clinical Oncology, Vol. 11, No. 1, 01.2014, p. 24-37.

Research output: Contribution to journalArticle

@article{2aaf1da3a7fd48999e063a5432a9cde9,
title = "Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer",
abstract = "Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints - whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.",
author = "Drake, {Charles G.} and Evan Lipson and Julie Brahmer",
year = "2014",
month = "1",
doi = "10.1038/nrclinonc.2013.208",
language = "English (US)",
volume = "11",
pages = "24--37",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Breathing new life into immunotherapy

T2 - Review of melanoma, lung and kidney cancer

AU - Drake, Charles G.

AU - Lipson, Evan

AU - Brahmer, Julie

PY - 2014/1

Y1 - 2014/1

N2 - Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints - whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.

AB - Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints - whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.

UR - http://www.scopus.com/inward/record.url?scp=84890980389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890980389&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2013.208

DO - 10.1038/nrclinonc.2013.208

M3 - Article

VL - 11

SP - 24

EP - 37

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 1

ER -